Menu
Back to User profile » Prof. Dr. Peter Bramlage
Papers published by Prof. Dr. Peter Bramlage:
Safety and effectiveness of a fixed-dose combination of olmesartan, amlodipine, and hydrochlorothiazide in clinical practice
Bramlage P, Fronk EM, Wolf WP, Smolnik R, Sutton G, Schmieder RE
Vascular Health and Risk Management 2015, 11:1-8
Published Date: 17 December 2014
Validation of the custo screen 400 ambulatory blood pressure-monitoring device according to the European Society of Hypertension International Protocol revision 2010
Bramlage P, Deutsch C, Krüger R, Wolf A, Müller P, Zwingers T, Beime B, Mengden T
Vascular Health and Risk Management 2014, 10:303-309
Published Date: 13 May 2014
Safety, tolerability, and efficacy of a fixed-dose combination of olmesartan 40 mg and hydrochlorothiazide 12.5/25 mg in daily practice
Bramlage P, Zemmrich C, Ketelhut R, Wolf WP, Fronk EM, Schmieder RE
Vascular Health and Risk Management 2013, 9:475-483
Published Date: 26 August 2013
Diabetes prevalence and metabolic risk profile in an unselected population visiting pharmacies in Switzerland
Rey A, Thoenes M, Fimmers R, Meier CA, Bramlage P
Vascular Health and Risk Management 2012, 8:541-547
Published Date: 21 September 2012
Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery
Turpie AG, Schmidt AC, Kreutz R, Lassen MR, Jamal W, Mantovani L, Haas S
Vascular Health and Risk Management 2012, 8:363-370
Published Date: 1 June 2012
Barriers to cardiovascular risk prevention and management in Germany – an analysis of the EURIKA study
Schmieder RE, Goebel M, Bramlage P
Vascular Health and Risk Management 2012, 8:177-186
Published Date: 15 March 2012
Office and ambulatory blood pressure control with a fixed-dose combination of candesartan and hydrochlorothiazide in previously uncontrolled hypertensive patients: results of CHILI CU Soon
Mengden T, Hübner R, Bramlage P
Vascular Health and Risk Management 2011, 7:761-769
Published Date: 12 December 2011
Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T)
Gerd Bönner, Bernhard Landers, Peter Bramlage
Vascular Health and Risk Management 2011, 7:85-95
Published Date: 17 February 2011
Effectiveness and tolerability of a fixed-dose combination of olmesartan and amlodipine in clinical practice
Peter Bramlage, Wolf-Peter Wolf, Thomas Stuhr, et al
Vascular Health and Risk Management 2010, 6:803-811
Published Date: 27 August 2010
Significance of initial blood pressure and comorbidity for the efficacy of a fixed combination of an angiotensin receptor blocker and hydrochlorothiazide in clinical practice
Roland E Schmieder, Markus Schwertfeger, Peter Bramlage
Vascular Health and Risk Management 2009, 5:991-1000
Published Date: 12 November 2009
Fixed combination of irbesartan and hydrochlorothiazide in the management of hypertension
Peter Bramlage
Vascular Health and Risk Management 2009, 5:213-224
Published Date: 11 February 2009